Long-term carperitide treatment attenuates left ventricular remodeling in rats with heart failure after autoimmune...

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Chronic heart failure (HF) remains a significant clinical challenge with limited treatment options.
• The therapeutic effects of carperitide, a recombinant human atrial natriuretic peptide, on chronic HF require further elucidation.
• Experimental autoimmune myocarditis serves as a relevant model for studying chronic HF progression.

Purpose of the Study:

• To investigate the beneficial effects of long-term carperitide administration in a rat model of chronic heart failure.
• To assess carperitide's impact on cardiac function, myocardial structure, and molecular signaling pathways.
• To determine if carperitide treatment influences neovascularization and vasodilator-stimulated phosphoprotein (VASP) activation.

Main Methods:

• Rats with experimental autoimmune myocarditis underwent a 28-day infusion of carperitide or vehicle.
• Evaluated myocardial cyclic guanosine monophosphate (cGMP) levels, left ventricular function, myocyte hypertrophy, and interstitial fibrosis.
• Assessed myocardial capillary vessel density and VASP phosphorylation status.

Main Results:

• Carperitide treatment significantly increased myocardial cGMP levels.
• Attenuated cardiac dysfunction, reduced myocyte hypertrophy and interstitial fibrosis, and increased the capillary-to-myocyte ratio.
• Enhanced VASP phosphorylation at Ser239, indicating activation of cGMP-dependent pathways and increased neovascularization.

Conclusions:

• Long-term carperitide treatment effectively attenuates ventricular remodeling and ameliorates chronic HF progression in rats.
• The beneficial effects are linked to increased neovascularization and enhanced VASP activation.
• Carperitide demonstrates potential as a therapeutic agent for chronic heart failure.